Chemical Science

ROYAL SOCIETY OF CHEMISTRY

CORRECTION

View Article Online
View Journal | View Issue

Cite this: *Chem. Sci.*, 2020, **11**, 12588

Correction: A straightforward approach to antibodies recognising cancer specific glycopeptidic neoepitopes

Hajime Wakui,[a] Yoshikazu Tanaka,[b] Toyoyuki Ose,[c] Isamu Matsumoto,[c] Koji Kato,[d] Yao Min,[c] Taro Tachibana,[e] Masaharu Sato,[f] Kentaro Naruchi,[f] Fayna Garcia Martin,[a] Hiroshi Hinou[a] and Shin-Ichiro Nishimura*[a]

DOI: 10.1039/d0sc90254c

rsc.li/chemical-science

Correction for 'A straightforward approach to antibodies recognising cancer specific glycopeptidic neoepitopes' by Hajime Wakui *et al.*, *Chem. Sci.*, 2020, **11**, 4999–5006, DOI: 10.1039/D0SC00317D.

The authors regret that part Fig. 1b was missing from the version of Fig. 1 shown in the original article. The correct version of Fig. 1 is presented below.

[a]*Field of Drug Discovery Research, Faculty of Advanced Life Science, Graduate School of Life Science, Hokkaido University, N21 W11, Kita-ku, Sapporo, 001-0021, Japan. E-mail: shin@sci.hokudai.ac.jp*

[b]*Graduate School of Life Sciences, Tohoku University, 2-1-1 Katahira, Aoba-ku, Sendai 980-8577, Japan*

[c]*Field of X-ray Structural Biology, Faculty of Advanced Life Science, Graduate School of Life Science, Hokkaido University, N10 W8, Kita-ku, Sapporo 060-0810, Japan*

[d]*Research Institute for Interdisciplinary Science and Graduate School of Natural Science and Technology, Okayama University, 3-1-1, Tsushima-naka, Kita-ku, Okayama 700-8530, Japan*

[e]*Department of Bioengineering, Graduate School of Engineering, Osaka City University, Sumiyoshi-ku, Osaka 558-8585, Japan*

[f]*Medicinal Chemistry Pharmaceuticals, Co., Ltd., N9 W15, Chuo-ku, Sapporo 060-0009, Japan*



b

Tn antigen: GalNAcα

T antigen: Galβ1,3GalNAcα

1 R_1-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr(**Tn**)-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala-Pro-Pro-Ala-His-Gly-Val-Thr-Cys-NH_2

2 R_1-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala-Pro-Pro-Ala-His-Gly-Val-Thr-Cys-NH_2

3 R_2-Val-Thr-Ser-Ala-Pro-Asp-Thr(**Tn**)-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala-NH_2

4 R_1-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr(**Tn**)-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala-Pro-Pro-Ala-NH_2

5 R_1-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr(**Tn**)-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala-Pro-Pro-Ala-NH_2

6 R_1-Val-Thr-Ser-Ala-Pro-Asp-Thr(**Tn**)-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala-Pro-Pro-Ala-NH_2

7 R_1-Thr-Ser-Ala-Pro-Asp-Thr(**Tn**)-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala-Pro-Pro-Ala-NH_2

8 R_1-Ser-Ala-Pro-Asp-Thr(**Tn**)-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala-Pro-Pro-Ala-NH_2

9 R_1-Ala-Pro-Asp-Thr(**Tn**)-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala-Pro-Pro-Ala-NH_2

10 R_1-Pro-Asp-Thr(**Tn**)-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala-Pro-Pro-Ala-NH_2

11 R_1-Asp-Thr(**Tn**)-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala-Pro-Pro-Ala-NH_2

12 R_1-Thr(**Tn**)-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala-Pro-Pro-Ala-NH_2

13 R_1-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr(**Tn**)-NH_2

14 R_1-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr(**Tn**)-Arg-NH_2

15 R_1-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr(**Tn**)-Arg-Pro-NH_2

16 R_1-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr(**Tn**)-Arg-Pro-Ala-NH_2

17 R_1-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr(**Tn**)-Arg-Pro-Ala-Pro-NH_2

18 R_1-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr(**Tn**)-Arg-Pro-Ala-Pro-Gly-NH_2

19 R_1-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala-Pro-Pro-Ala-NH_2

20 R_1-His-Gly-Val-Thr(**Tn**)-Ser-Ala-Pro-Asp-Thr(**Tn**)-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala-Pro-Pro-Ala-NH_2

21 R_1-His-Gly-Val-Thr-Ser(**Tn**)-Ala-Pro-Asp-Thr(**Tn**)-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala-Pro-Pro-Ala-NH_2

22 R_1-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr(**Tn**)-Arg-Pro-Ala-Pro-Gly-Ser(**Tn**)-Thr-Ala-Pro-Pro-Ala-NH_2

23 R_1-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr(**Tn**)-Arg-Pro-Ala-Pro-Gly-Ser-Thr(**Tn**)-Ala-Pro-Pro-Ala-NH_2

24 R_1-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr(**T**)-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala-Pro-Pro-Ala-NH_2

25 R_2-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr(**Tn**)-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala-Pro-Pro-Ala-Cys-NH_2

R_1=$CH_3CO(CH_2)_3CO$ R_2=CH_3CO

Fig. 1 Generation of epitope-defined anti-MUC1 antibodies. (a) A strategy for the generation of antibodies targeting glycopeptidic epitopes by using synthetic glycopeptides designed for the streamlined process from the immunization of "conformational glycopeptidic neoepitopes", antibody selection, and characterization. (b) A list of compounds used in this study. Compound **1** was conjugated with KLH by using the Cys residue (red) or aminooxy-functionalized nanoparticles[25–27] by using the ketone linker (blue) and used for the immunization. The first screening was performed by ELISA immobilizing compounds **1** and **2** using Cys residue (red) to collect antibodies binding selectively with glycopeptide **1**. Compound **3** was used for the co-crystallization with SN-101. Compounds **4**–**24** were displayed on the microarray by means of the ketone linker (blue) and employed for epitope mapping analysis. Compound **25** was used for the SPR analysis by immobilizing with Cys residue (red).

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.